CRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to ...

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...

BioAge Labs said its investigational pill for cardiovascular risk prevention significantly reduced inflammation in an early ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong ...

BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...

An uptick in initial public offering (IPO) filings in recent weeks suggests that the market for first-time biotech stocks is finally recovering after three years of sparse activity capped by share ...

Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...

The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...

BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and ...

BioAge now offering 10.5 mln shares, vs 7.5 mln earlier Sofinnova expected to invest up to $1.4 mln in IPO Investment firm expected to buy shares worth $10.6 mln in private placement Sept 25 (Reuters) ...